Revisiting CDKN2A dysregulation in Ewing sarcoma
High expression of CDKN2A is a negative prognostic biomarker at diagnosis in Ewing sarcoma in three independent datasets.
Ewing sarcoma (EwS) is a rare and aggressive malignancy, which frequently affects children. One of the few recurrent genomic variants in EwS is genomic copy number deletion of CDKN2A; however, the clinical consequences of dysregulation of CDKN2A in EwS are unclear. In this study, we revisit CDKN2A to investigate its role as a potential prognostic biomarker in EwS using data from EwS pre‑clinical models as well as clinical samples from patients with EwS. We demonstrate the potential essentiality of CDKN2A dysregulation and sustained downstream CDK4 / CCND1 activity. Finally, we present evidence that high expression of CDKN2A is a negative prognostic biomarker at diagnosis in EwS in three independent datasets. Our data may suggest that the role of CDKN2A may change across the clinical context of EwS, however, further study is necessary to validate the function of CDKN2A expression in EwS.
Understanding the prognostic value of CDKN2A expression and its downstream pathway activity in Ewing sarcoma can guide risk stratification and inform therapeutic strategies, particularly the use of CDK4/6 inhibitors, potentially improving patient outcomes.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Emerging therapies in Ewing sarcoma
- Genome‑wide association study meta‑analysis identifies susceptibility loci informing Ewing sarcoma etiology and potential mechanisms of risk
- Biochemists discover new strategy to combat pediatric bone cancer
- Integrated Immunotherapy Target Atlas for Ewing Sarcoma
- Rewiring the fusion oncoprotein EWSR1::FLI1 in Ewing sarcoma with bivalent small molecules